Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Martek

This article was originally published in The Tan Sheet

Executive Summary

Company's nutritional oils enriched with docosahexaenoic acid (DHA) and arachidonic acid (ARA) will be sold in term infant formulas in the U.K., Martek Biosciences announces March 6. Wyeth Nutritionals International, a subsidiary of Wyeth-Ayerst Pharmaceuticals, will include ingredients in SMA Gold term infant formula. FDA is reviewing DHA/ARA as ingredients in formulas to be marketed in U.S.; Martek expects a decision within the year. The firm also announces March 2 completion of approximately $20 mil. in financing with investor group, selling over 1.2 mil. shares of its common stock and issuing warrants to purchase 319,811 shares
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS092280

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel